Raluca Ioana van Staden

Haideti sa mai vorbim si despre romani (desi ar cam trebui sa stiti despre ce e vorba mai jos)
Cercetatoarea Raluca-Ioana van Staden a castigat, in cadrul Salonului International de Inventii de la Geneva, Trofeul de Aur al Organizatiei Mondiale pentru Proprietate Intelectuala pentru “Cea mai buna femeie inventator”.
Dispozitivul inventat de cercetatoare impreuna cu sotul ei Jacobus Frederick van Staden, este un senzor care poate determina existenta cancerului in corpul uman, in mai putin de 6 minute si inainte ca boala sa fie declansata in corp.
Intr-un interviu cu specialista proaspat laureata la Geneva. Raluca-Ioana van Staden a vorbit despre dispozitivul care i-a adus Trofeul de Aur la Geneva si despre planurile de a-l produce pe scara larga.
“Este vorba despre un nou tip de senzor care determina atat calitatea biomarkerului, ajutand doctorul la diagnosticarea tipului de cancer, cat si cantitatea, ajutandu-l sa decida ce medicament administreaza si in ce masura pentru ca boala sa nu evolueze. 
Noi am facut experimente deja pe diverse tipuri de cancer, ovarian, de san, gastrointestinal si de prostata, precum si cu markeri generali de cancer.
Noi facem o detectie inainte ca boala sa fie declansata in corp.
Rezultatele sunt fiabile si spre deosebire de alti senzori nu e nevoie de o calibrare prealabila, asta pentru ca principiul de functionare este unul mai deosebit”, sustine cercetatoarea romana.
Productia acestui dispozitiv va incepe foarte curand, in parteneriat cu o companie romaneasca, astfel incat produsul va fi “pur romanesc”, a mai aratat cercetatoarea.
Costurile de testare ale dispozitivului sunt foarte mici – sub un euro.
“In momentul de fata avem in vedere o suma de sub un euro. Ne gandim la niste costuri care sa poata fi preluate de Casa de Asigurari de Sanatate , astfel incat testarile sa nu mai fie un lux, ca in prezent. Produs pe scara larga, dispozitivul ar fi foarte usor de utilizat, la fel de usor ca un glucometru”, a mai aratat Raluca-Ioana van Staden.
Dupa ce va fi aprobat de catre Ministerul Sanatatii, senzorul va fi distribuit in spitalele romanesti, iar Romania va fi prima tara care il va folosi, a declarat omul de stiinta la Realitatea TV.
Sa vedem si daca va fi utll(precis si non-toxic) cum se spune. Eu sunt oarecum sceptic avand in vedere folosirea sa in corelatia cu „cantitea de medicatie necesara” dar vom vedea rezultatele.
Faptele vorbesc si la testul PSA si la mamografii si la multe altele
Intre timp avem deja teste si non-toxice si precise , personalizate dupa tip de cancer ce pot detecta tumorile cu zece ani inainte de metodele promovate actual in lume (asa cum e termografia) si se gasesc exceptii(a se vedea centrul termografic al Dr Muresan din Cluj) , de ce nu se implementeaza pe scara larga si trebuei sa apelam la straini sa monitorizam progresl tratamentului cancer (desi si strainii sunt tot marginalizati)?
Raluca-Ioana van Staden a participat in ultimii trei ani la 6 proiecte nationale de cercetare si a coordonat proiecte de cercetare in Africa de Sud, la Universitatea din Pretoria.
Potrivit site-ului Fundatiei Dinu Patriciu, doamna van Staden a obtinut in cadrul Facultatii de Chimie, din cadrul Universitatii din Bucuresti, diplomele de licenta si de doctorat, dar a urmat si cursurile unei a doua facultati, studiind Pian si Pedagogie muzicala in cadrul Universitatii Nationale de Muzica, urmate de un master in Compozitie. In prezent lucreaza la PATLAB, prescurtarea pentru Laboratorul de Tehnologie Analitica de Proces, filiala din Bucuresti a Institutului de Electrochimie si Materie Condensata Timisoara, o parte a activitatii sale desfasurandu-se in prezenta studentilor.


Testul PSA – NICI un beneficiu in 99.9% cazuri

Click aici pentru limba romana

PSA screening exposed as complete medical hoax: 99.9 percent of the time it provides no benefit to men

Tuesday, May 07, 2013 by: Ethan A. Huff, staff writer

(NaturalNews) The medical-industrial complex is backtracking heavily these days from recommending that men undergo prostate-specific antigen (PSA) tests for prostate cancer, as continually emerging evidence reveals the test to be dangerous, inaccurate, and essentially useless for most men. In fact, the American Urological Association (AUA) at its recent annual meeting admitted that, based on the available data, PSA tests provide no benefit to men 99.9 percent of the time, which by any reasonable standards renders the test a complete hoax.

Because of this incredibly dismal failure rate, the AUA is now recommending that men younger than 55 and older than 70 not get PSA tests at all. And for those within this age range who do choose to undergo screening, the AUA recommends that they first have a thorough and lengthy discussion with their doctors about the potential risks, which include false positives and a slew of harmful side effects such as impotence and incontinence.

The new recommendation aligns with that of the American College of Physicians (ACP), which last month suggested that PSA tests be administered on a case-by-case basis depending on an individual patient’s risk, and only to men in their 50s and 60s. Like the AUA, the ACP also urges men to first consult with their physicians to discuss not only the general risks associated with PSA tests, but also the personal likelihood of sustaining harmful side effects.

„I look upon this guideline … as the beginning of a targeted-based screening,” says Dr. H. Ballentine Carter, chair of the panel that developed the AUA’s new guidelines, and a urologist and oncologist atJohns Hopkins Hospital in Baltimore, Maryland. „Instead of a one-size-fits-all approach, we’re trying to emphasize that there is a group of men between age 55 and 69 that are much more likely to benefit.”

Government task force says nobody should get screened using PSA tests

But is the legitimacy of PSA tests for any age group at all verifiable by science? The U.S. Preventive Services Task Force (PSTF), a government agency that investigates such matters, does not seem to think so, having discovered last year that PSA tests are wholly unreliable; they tend to lead to many false positives; and they do not increase either lifespan or quality of life, contrary to popular belief.

„There is a small potential benefit and a significant known harm,” says Dr. Virginia A. Moyer, a professor of pediatrics at Baylor College of Medicine in Houston, Texas, and chair of the PSTF. Based on their findings, Dr. Moyer and her research team are basically now advising that male patients in all age categories avoid PSA tests entirely.

Similar conclusions were arrived at by the AUA, with the noteworthy exception that this particular group is not advocating against PSA tests entirely. Instead, the group hopes both patients and doctors will be more aware of the risks, which are much more prevalent and likely to occur than any alleged benefits. As it turns out, only one additional man out of every 1,000 men screened with a PSA test will avoid death, while many more will suffer harmful side effects or incur permanent health damage as a consequence of it.

„The evidence for the benefits of prostate cancer screening was moderate, but the quality of evidence on the harms was high,” adds Dr. Carter, as quoted by Reuters. „The idea that screening delivers benefits may have been over-exaggerated.”

Sources for this article include:

Learn more: